期刊
PHARMACEUTICS
卷 14, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics14020254
关键词
doxorubicin; liposomes; micelles; metal-organic frameworks (MOFs)
资金
- Dana Gas Endowed Chair for Chemical Engineering
- American University of Sharjah Faculty Research Grants [eFRG18-BBRCEN-03]
- Sheikh Hamdan Award for Medical Sciences [MRG/18/2020]
- [AJF 2015555]
- [BBRI18-CEN-11]
- [IRF17-003]
- [POC-00028-18]
- [OAPCEN-1410-E00014]
- [FRG20-L-E48]
Doxorubicin, a widely used anticancer drug, can be encapsulated in nanoparticles to achieve localized and controlled delivery, reducing toxicity to healthy cells.
Doxorubicin (DOX) is one of the most widely used anthracycline anticancer drugs due to its high efficacy and evident antitumoral activity on several cancer types. However, its effective utilization is hindered by the adverse side effects associated with its administration, the detriment to the patients' quality of life, and general toxicity to healthy fast-dividing cells. Thus, delivering DOX to the tumor site encapsulated inside nanocarrier-based systems is an area of research that has garnered colossal interest in targeted medicine. Nanoparticles can be used as vehicles for the localized delivery and release of DOX, decreasing the effects on neighboring healthy cells and providing more control over the drug's release and distribution. This review presents an overview of DOX-based nanocarrier delivery systems, covering loading methods, release rate, and the cytotoxicity of liposomal, micellar, and metal organic frameworks (MOFs) platforms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据